Neurofibromatosis News and Research

Latest Neurofibromatosis News and Research

CTF, DELopen jointly offer unique opportunities to neurofibromatosis research community

The Children's Tumor Foundation, an innovative and global neurofibromatosis (NF) research foundation announced today a collaboration with DELopen, a DNA-encoded library technology platform sponsored by WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries.

19 Nov 2019

FDA grants acceptance to application for selumetinib as treatment for neurofibromatosis

AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1).

14 Nov 2019

Researchers uncover novel molecular clues for tumor aggression in neurofibromatosis type 1

Researchers at the Johns Hopkins Kimmel Cancer Center report that their study of tumor samples from people with the rare genetic syndrome neurofibromatosis type 1 (NF1) has uncovered novel molecular clues about which tumors are most likely to be aggressive in those with NF1

From Johns Hopkins Medicine 18 Oct 2019

New grants support research on mechanics of tumor cells

At the cellular level, cancer can be viewed as a mechanical engineering challenge. The disease alters the structure and function of cells and tissues, which are meant to perform very specific tasks.

8 Oct 2019

Children's Tumor Foundation harnesses interest in rare disease research through NF Innovation Week

Neurofibromatosis, a genetic disorder that causes tumors to grow on nerves throughout the body and which affects 1 in 3,000 people - that's over 2.5 million worldwide - has no cure and few workable treatment options.

15 Sep 2019

Researchers open up possible avenue for new cancer treatments without side effects

Researchers have opened up a possible avenue for new cancer therapies that don't have the side effects that oftentimes accompany many current cancer treatments by identifying a protein modification that specifically supports proliferation and survival of tumor cells.

6 Aug 2019

Targeting immune cells could potentially treat some kinds of brain tumor, study suggests

Tumors arise when cells shake off their restraints and start to multiply out of control. But how fast a tumor grows does not depend solely on how quickly the cancer cells can divide, a new study has found.

4 Jun 2019

Children's Tumor Foundation establishes significant research initiative to combat NF2

On the occasion of World NF2 Awareness Day, the Children's Tumor Foundation has announced the establishment of a significant research initiative dedicated to finding effective treatments for NF2, along with a substantial investment of $2.3 million in this bold new effort.

23 May 2019

Study discovers origin of neurofibromas that develop throughout the skin of NF1 patients

A study published today in PLOS ONE discovered the origin of severely disfiguring masses of cells, called neurofibromas, that gradually develop throughout the skin of patients afflicted with Neurofibromatosis 1.

22 May 2019

Research into cancer signaling network reveals new roadmap to tumor control

In this advanced age of molecular sleuthing, a research team led by Georgetown Lombardi Comprehensive Cancer Center have findings that suggest tumors will eventually become resistant to drug inhibitors of a common cancer pathway (dubbed YAP/TAZ), now in preclinical development.

7 May 2019

Royal Holloway professors to lead new to research into curing Neurofibromatosis type 1

Linda Popplewell, Lecturer in Biomedical Sciences, and world-renowned Professor George Dickson, from the School of Biological Sciences, both at Royal Holloway, will lead a team looking for a treatment for NF1, a genetic disorder that causes tumors to form on nerve tissue.

20 Mar 2019

Mice sleeping fitfully help unravel mystery of insomnia

Mice that sleep fitfully could help researchers unravel the mystery of insomnia. Researchers at Washington University School of Medicine in St. Louis studied mice genetically modified to mimic the genetic disease neurofibromatosis type 1, which is associated with sleep problems.

9 Jan 2019

Scientists move one step closer towards treatment for low-grade gliomas with SYNODOS

Treatment for low-grade gliomas in patients living with neurofibromatosis type 1 are now one step closer thanks to recent research discoveries initiated and funded by the Children's Tumor Foundation.

28 Dec 2018

CTF along with NTAP and Sage announce first-ever open data portal for neurofibromatosis

The Children's Tumor Foundation, together with the Neurofibromatosis Therapeutic Acceleration Program and Sage Bionetworks, has announced the first-ever open data portal for scientific research results in the field of neurofibromatosis.

17 Dec 2018

Slow-growing type of glioma may be vulnerable to immunotherapy, suggests study

Immunotherapy has proved effective in treating a number of cancers, but brain tumors have remained stubbornly resistant.

11 Dec 2018

Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1

International collaborative research led by Ludwine Messiaen, Ph.D., shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis type 1, or NF1, the mutation does cause complications.

18 Sep 2018

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene's investigational RAF dimer inhibitor, lifirafenib and SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors.

6 Sep 2018

Neurofibromatosis News and Research

Latest Neurofibromatosis News and Research

CTF, DELopen jointly offer unique opportunities to neurofibromatosis research community

FDA grants acceptance to application for selumetinib as treatment for neurofibromatosis

Researchers uncover novel molecular clues for tumor aggression in neurofibromatosis type 1

New grants support research on mechanics of tumor cells

Children's Tumor Foundation harnesses interest in rare disease research through NF Innovation Week

Researchers open up possible avenue for new cancer treatments without side effects

Targeting immune cells could potentially treat some kinds of brain tumor, study suggests

Children's Tumor Foundation establishes significant research initiative to combat NF2

Study discovers origin of neurofibromas that develop throughout the skin of NF1 patients

Research into cancer signaling network reveals new roadmap to tumor control

Royal Holloway professors to lead new to research into curing Neurofibromatosis type 1

Mice sleeping fitfully help unravel mystery of insomnia

Scientists move one step closer towards treatment for low-grade gliomas with SYNODOS

CTF along with NTAP and Sage announce first-ever open data portal for neurofibromatosis

Slow-growing type of glioma may be vulnerable to immunotherapy, suggests study

Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

Researchers find how NF2 gene mutations lead to out-of-control cellular proliferation

RDMD raises $3 million in seed funding to accelerate rare disease research, drug development

EMA grants orphan designation to selumetinib for treatment of neurofibromatosis type 1

Neuroscience - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Neurofibromatosis News and Research

Latest Neurofibromatosis News and Research

Neuroscience - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in